RIOX2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1171098	0.49	8/20
SCHEMBL9318375	0.46	8/20
SCHEMBL9318569	0.46	8/20
SCHEMBL9319224	0.48	7/20
SCHEMBL9318758	0.46	7/20
SCHEMBL8220004	0.45	7/20
SCHEMBL3630642	0.39	7/20
SCHEMBL9319920	0.45	6/20
SCHEMBL2097727	0.41	6/20
SCHEMBL9400529	0.70	5/20
SCHEMBL686861	0.48	5/20
SCHEMBL3242847	0.41	5/20
SCHEMBL1397838	0.39	5/20
SCHEMBL5158867	0.50	4/20
SCHEMBL3730790	0.76	3/20
SCHEMBL11390531	0.62	3/20
SCHEMBL4897624	0.62	3/20
Enfenamic Acid (SCHEMBL25191)	0.60	3/20
SCHEMBL14881168	0.59	3/20
Enfenamic Acid (SCHEMBL10935569)	0.58	3/20

Clinical trials — most relevant to RIOX2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
A Prevention Trial in Subjects at High Risk for Breast Cancer	PHASE2	COMPLETED
Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.	PHASE2	COMPLETED
KRAS Wild-type Metastatic Colorectal Cancer Trial	PHASE1	COMPLETED
Role of TLR4 in Environmental Asthma	PHASE1	COMPLETED
Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids	PHASE1	COMPLETED
Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia	PHASE1	RECRUITING
Breakpoint Analysis of de Novo Apparently Balanced Chromosomal Translocations	EARLY_PHASE1	COMPLETED
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
The Genetics of Environmental Asthma	nan	COMPLETED
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Positional Cloning of the Gene(s) Responsible for Alagille Syndrome	nan	COMPLETED
Cell Signaling and Resistance to Oxidative Stress: Effects of Aging and Exercise	nan	COMPLETED
ASO Treatment for Syndromic Craniosynostoses	nan	NOT_YET_RECRUITING
High Altitude Medical Research Expedition Himlung 2013 - a Study of Human Adaption to Hypoxia	nan	COMPLETED
Stress and Treatment Response in Puerto Rican Children With Asthma	nan	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Investigation of Copy Number Variations and Genetic Variants in POI	nan	RECRUITING
Chilean Gastric Cancer Task Force (FORCE 1)	nan	COMPLETED
Somatosensory Modulation of Salivary Gene Expression and Oral Feeding in Preterm Infants	nan	COMPLETED
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve	nan	UNKNOWN
Genetic Factors Affecting the Severity of Beta Thalassemia	nan	COMPLETED
The Sapienza University Mortality and Morbidity Events Rate (SUMMER) Study in Diabetes	nan	COMPLETED
Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia	nan	UNKNOWN
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes	nan	UNKNOWN
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RIOX2 binder may also engage these)

Protein	Name	Similarity
Q5R673	—	1.000	Q5R673 →
Q5EA24	—	1.000	Q5EA24 →
Q8CFC1	—	0.999	Q8CFC1 →
Q8CD15	—	0.983	Q8CD15 →
A3KP59	—	0.982	A3KP59 →
Q80VP9	—	0.977	Q80VP9 →
Q28DV7	—	0.976	Q28DV7 →
Q8N1G2	—	0.976	Q8N1G2 →
Q6PDS3	—	0.976	Q6PDS3 →
F1ND48	—	0.976	F1ND48 →
Q96BT7	—	0.976	Q96BT7 →
MDN1	Midasin	0.975	landscape →
Q5U2X1	—	0.975	Q5U2X1 →
Q5IH13	—	0.975	Q5IH13 →
Q95K79	—	0.975	Q95K79 →
SMCHD1	Structural maintenance of chromosomes flexible hinge domain-containing protein 1	0.975	landscape →
Q6AZT7	—	0.975	Q6AZT7 →
Q8VDY4	—	0.975	Q8VDY4 →
Q5R981	—	0.975	Q5R981 →
Q3V3E1	—	0.975	Q3V3E1 →
Q5R5S1	—	0.975	Q5R5S1 →
Q6DC53	—	0.974	Q6DC53 →
Q9DBC3	—	0.974	Q9DBC3 →
O00423	—	0.974	O00423 →
Q8K4M9	—	0.974	Q8K4M9 →
Q5T8I9	—	0.974	Q5T8I9 →
Q3U3W5	—	0.973	Q3U3W5 →
A0JMH0	—	0.973	A0JMH0 →
Q9EPU4	—	0.973	Q9EPU4 →
Q8C0L9	—	0.973	Q8C0L9 →